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875-5 Antiinflammatory and Antiangiogenetic Effect of 
Ramiprilat: Angiotensin Converting Enzyme Inhibition 
in Monocytes Prevents Their Angiotensin II- and 
Hypoxia-Induced Cytokine Expression by 
Downregulation of AT-1 Receptor Expression and NF- 
kappa6 Activation 
Alexander Schmeisser, Oliver Soehnlein, Thomas Illmer, Christoph Garlichs, Hannes 
Lorenz. Gerhard Ehninaer. Werner G. Danrel. Ruth H. Strasser. Technical Universitv of 
Dresden, Dresden, Germany, University Erlangen-Nuernberg, Erlangen, Germany 
Background: There are several controversal reports regarding the effects of ACE inhibi- 
tors on the plaque angrogenesis in atherosclerosis and tumor growth. An antiinflamma- 
tory and antiangiogenic effect of ACE-inhibition might be of major relevance in acute 
coronary syndromes. Because the Angrotensin II (ATII)-ATl-receptor(R)- and hypoxia- 
derived angiogenesis is induced by supporting mononuclear cell (MNC) infiltration and 
angiogenic cytokine expression we examined the effects of ACE inhibition on the stimu- 
lation of Monocytes by ATII and hypoxia. 
Methods: Human MO were stimulated rn vitro 1. with 100 and 500 nM ATII and 2. with 
hypoxia (02:3%). In 1. MO were pretreated with 1 ,B,lOmicroM ramiprilat @a), ATl-R 
Inhibitor (I) Losartan (1microM) or AT2-RI PDl23,319 (1microM) and in 2. with 
1 ,S,lOmicroM Ra. Analysis of monocytic ATIR-R expression was performed by western 
blotting, NF-kappaB by EMSA, IL-8 and MCP-1 by RT-PCR and ELISA, statistics by sto- 
dents t-test (sign: p-zO.05). In 10 samples of advanced human atherosclerotic carotid 
plaques (AHP) immunohrstochemic starning for ACE, IL-8 and MCP-1 was performed. 
Results: In 100% of inflammatory shoulder regions of AHP colocalization of MNC-ACE 
with MCP-1 and IL-8 could be demonstrated. In vitro, hypoxia stimulated MO IL-8 and 
MCP-1 expression was inhibited with Ra by 65+/-13% and 48+/-l 1% (PcO.01). respec- 
tively. MO ATII-ATl-R induced IL-8 and MCP-1 expression could also Inhibited by 49+1- 
4% and 71+/-5% with Ra rn dose-dependent manner. Ra (10microM) reduced the 
hypoxia- and ATII-induced NF-kappaB actrvation only slightly (p=O.8). But, Ra 
(IOmicroM) reduced the monocyte ATI-R expression by 50+/-12% and 83+/-13% after 
12 and 24h highly significant (pcO.001). The ATP-R expression remarned unchanged. 
Conclusion: For the first time, it could be demonstrated that antrinflammatory effects of 
ACE inhibition could be derived by a marked downregulation of monocytic AT1 -R expres- 
sion, and by an Inhibition of the hypoxra-induced proinflammatory and angiogenic MCP-1 
and IL-8 productron. These effects of Ra mrght be of major relevance in atherosclerotic 
plaque vulnerabrlity. 
9:45 a.m. 
875-8 Effect of Exercise Training in Patients With Coronary 
Artery Disease on Circulating Endothelial Progenitor 
Cells 
Karsten Lenk, Volker Adams, Marcus Sandri, Atila Tarnok, Dominik Lens, Andrej 
Schmidt, Dirk Scheinert, Dirk Schetnert. Gerhard Schuler, Rainer Hambrecht. Universrty 
of Leipzig, Heart Center, Leipzig, Germany 
In patients with coronary artery disease (CAD) exercrse training (ET) is regularly associ- 
ated with a decrease in exercise-induced myocardial ischemia. Recently it has been 
shown that a symptom-limited exercrse test is sufhcrent to increase circulating endothslral 
progenitor cells (EPC) in patients with symptomatrc CAD. Until now, however less IS 
known about the impact of regular ET on the amount of circulating EPCs. Aim of thus 
stodv was to investroate the effects of ET on the number of EPCs in oatrents with svfno- 
tomatic CAD. To define the role of ischemia during ET we also analyzed the effect‘of 
treadmill trainino in oatrents with oerioheral arterv occlusive disease iPAODI bevond the _ i ,  
ischemic threshold. 14 patients with CAD and 14 patients with PAOD were randomly 
assigned either to (ET) or an inactive control group (C). Ergometer and treadmill training 
was performed 6 times daily for a period of 4 weeks. The concentration of EPCs was 
analyzed by FACS-analysis of CD34+/KDR+ cells. In cell culture the amount of EPCs 
was determined by analyzing Di-LDL and FITC-Lectin double positive stained cells using 
Laser Scanning Cytometry. After 4 weeks of ET crrculating EPCs showed ho srgnificant 
differences in IP rn comparison to baseline levels (cell culture: 1.6+0.5fold increase ; n.s. 
vs. baseline and C ; FACS: 1.3*0.3fold increase , n.s. vs. baseline and C). In PAOD 
patients regular ET leads to a significant increase of EPC during the training period with a 
peak after 3 weeks (cell culture: 6.2+3.4fold increase ; peO.01 vs. baseline and C ; 
FACS: 3.2+1.8fold increase , p<O.Ol vs. baseline and C). In conclusion, the present 
study demonstrates that exercise training in symptomatic CAD patients below the 
ischemic threshold is Insufficient to induce an increase in the number of circulating EPCs. 
In contrast treadmill training in PAOD patients beyond the ischemfc threshold seems to 
be a potent trigger for an EPC release. 
8:30 am. 
876-1 Aggressive Treatment Aimed at Raising High-Density 
Lipoprotein Cholesterol in Stable Patients With 
Angiographically Evident Coronary Disease Prevents 
Stenosis Progression and Reduces Cardiovascular 
Events 
Richard A. Krasuski Ara M. Maranian, Edwrn J. Whitney, Bradley E. Personios, B. Greg 
Brown, Antonio M. Gotto, Jr., Wilford Hall Medical Center, San Antonio, TX 
Background: Overwhelming evidence supports that lowering low-density lipoprotein 
cholesterol (LDL-c), particularly with statins, leads to a reduction in cardiovascular 
events. High-density lipoprotein cholesterol (HDL-c). despite being a stronger predictor 
of events in epidemiologic studies, has been mostly neglected es the focus of therapy. 
Methods: We performed a randomized double-blind, placebo-controlled trial assessing 
the effect of gemfibrozil, niacin, and cholestyramrne on a baseline of aggressive dretary 
and lifestyle intervention. Patrents ~76 years of age with angiographically-evident coro- 
nary disease in the absence of recent instability were consented and followed over a 
period of 30 months. Quantitative angiography was performed at baselrne and at the 
completion of the study. 
Results: In the 143 randomized patients, mean age was 63 * 7 years and 8% were 
women. Baseline characteristics included total cholesterol 195 * 31 mgldl, LDL-c 127 * 
27 mgidl, HDL-c 34 i- 6 mg/dl, triglycehdes 169 * 82 mg/dl. systolic blood pressure 139 * 
16 mm Hg, and fashng blood sugar 80 f 14 mgldl. No difference in baseline characteris- 
tics was seen between the 2 groups. Median weight loss during the study was 1% in the 
placebo group and 4% in the drug group, p-zO.001. Total cholesterol increased by 3% in 
the placebo group but was reduced by 16% in the drug group, p<O.OOl. LDL-c increased 
by 21% in the placebo group but dropped by 5% in the drug group, p<O.OOl. HDL-c 
increased by 2% in the placebo group and by 37% in the drug group, p<O.OOl. Triglycer- 
Ides increased by 3% in the placebo group but were reduced by 45% in the drug group, 
pcO.001. Fasting blood sugar increased by 8% oh placebo group and by 18 % on drug 
therapy, p=O.O06. Focal coronary stenosis increased by 1% on placebo but decreased by 
1% in the drug group, p=O.O43. A combined endpoint of unstable angina, transient 
ischemic attack and stroke, percutaneous intervention, coronary bypass, or death was 
reached in 19 placebo patients and 9 drug patients, p=O.O39. 
Conclusion:A combination of agents aimed at increasing HDL-c dramatically knproves 
cholesterol profiles, arrests angiographic progression, and results in a significant reduc- 
tion in cardiovascular events. 
8:45 a.m. 
876-2 Statin Therapies for Elevated Lipid Levels Compared 
Across Dose Ranges to Rosuvastatin: Low-Density 
Lipoprotein Cholesterol and High-Density Lipoprotein 
Cholesterol Results 
Peter H. Jones for the STELLAR Study Group, Baylor College of Medicine, Houston, TX 
Background: The primary objective of this large, multicenter trial was to compare the 
effects of rosovastatin (RSV) versus atorvastatin (ATV), simvastatin (SIM), and pravasta- 
tin (PRA) across dose ranges on percent changes in low-density lipoprotein-cholesterol 
(LDL-C). 
Methods: After discontinuation of lipid-lowering drugs and a 6.week dietary lead-in 
period, 2431 adults with hypercholesterolemia (LDL-CY60 mg/dL and ~250 mg/dL; trig- 
lycerides ~400 mg/dL) were randomrzed to 15 parallel, open-label treatments for 6 
weeks. Treatments in this trial (4522lUOO65) included RSV 10, 20, 40, or 80 mg; AlV 10, 
20, 40, or 80 mg; SIM 10, 20, 40, or 60 mg; and PRA 10. 20, or 40 mg. Prospectively 
planned analyses for each lipid included log-dose-response curve analyses and 25 
selected pair-wise comparisons of RSV doses with corresponding or higher doses of 
comparators (with a statistical significance level adjustment to 0.002 to account for multi- 
ple compahsons). 
Results: The table shows dose-to-dose comparisons. Baselrne LDL-C means were 187 
to 194 mg/dL. The curves analysis showed that RSV produced a mean 8.2% greater 
LDL-C reduction (pc.001) than AN across the dose ranges. Greater differences in LDL- 
C reduction were observed between RSV and PRA or SIM. 
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Least-square mean % changes in LDL-C and high-density lipoprotein-C (HDL-C) from 
baseline from analysis of variance 
RSV ATV SIM PRA 
N/group, range 156-161 154-165 158.165 160.164 
LDL- HDL- LDL- HDL-C LDL-C HDL-C LDL-C HDL-C 
c c C 
10 mg -46 +7.6 -37w c5.7 -2ec’) +5.3 -20 @I +3.2 ra) 
20 mg -52 +9.4 -43s) +4,8(b) _35@,sl +6.0 _24(a,b) +44(b) 
40 mg -55 +9.6 - +44(0) - +5.@ - +5.5(b.C 
48(b.C) 3?$8.b.C Cl 30(a,s,c,o , 
) ) 
80 mg -58 +8.5 .51(d) +2.0(0 +6.8 
d) @C.d 
Conclusion. Fenofibrate significantly reduced small, dense LDL. The mean reduction in 
small LDL (-28.5%) was balanced by an increase in large LDL (+22.7%) explaining the 
lack of change in total LDL. Fenofibrate reduced the smallest LDL (IVb) which has been 
independently linked to arteriographic progression in the Stanford Coronary Risk Inter- 
vention Project. 
Significantly different (pc.002) compared with@)RSV 10 mg, @)RSV 20 mg. @)RSV 40 
mg, @)RSV 80 mg 
676-3 On-Treatment Increments in Serum High-Density 
Lipoprotein Levels Are Associated With Improved 
Survival in Patients With Coronary Heart Disease: An 
Extended Follow-Up of the Bezafibrate Infarction 
Prevention Trial 
llan Goldenberg Uri Goldbourt, Valentina Boyce. Solomon Behar, Henrietta Reicher- 
Conclusions: Across doses, RSV was more effective in lowering LDL-C than AN, SIM, Ernst Schaefer, Errol Gould, Tufts University School of Medicine, Boston, MA, 
and PRA. RSV consistently raised high-density lipoprotein-cholesterol at all doses. GlaxoSmithKline, Collegeville, PA 
9:oo a.m. 
Background: While the primary target for lipid-lowenng therapy is low-density lipopro- 
tein cholesterol, recent guidelines stats that a high-density lipoprotein cholesterol 
(HDLC) level ~40 mg/dL necessitates intervention due to an increased risk of cardiovas- 
cular disease (CVD). The total cholesterol:HDLC ratio is also important for stratifying 
CVD risk. 
Methods: We retrospectively examined the long-term effect of the antidiabetic agent 
rosiglitazone (RSG) on HDLC using subanalyses of data from 269 patients with Type 2 
diabetes who took RSG 8 mgiday for 24 months in open-label extensions of 2 similarly 
designed placebo-controlled double-blind studies. Data were analyzed according to 
baseline HDLC values (<40 or?40 mg/dL) and total cholesterol:HDLC (~5 orz5). 
Results: HDLC concentration continued to increase over 24 months of RSG treatment, 
representing a mean increase from baseline of 25% in the HDLC ~40 mg/dL group and 
10% in the HDLC z40 mg/dL group. For all patients, total cholesterol:HDLC decreased 
from 5.06 to 4.70 over the 24-month RSG treatment period. In patients with total choles- 
terol:HDLC s the mean ratio decreased from 6.25 to 5.60 after 24 months. In patients 
with total cholesterol:HDLC c5 the mean ratio decreased from 3.92 to 3.88 after 24 
months. 
Relss, Heart Institute. Sheba Medical Cernter, Tel Hashomer, Israel 
Background Low serum HDL cholesterol (HDL-C) predicts coronary heart disease 
(CHD). The Bezafibrate Infarction Prevention (BIP) trial was designed to assess the eff- 
cacy of raising HDL-C in CHD patients with HDL-C <45 mg/dL. In this analysis of an 
extended 8.2-year follow-up of the trial we evaluated the association between HDL-C 
modification and all-cause and cardiac mortality. Methods Study patients were random- 
ized to receive either bezafibrate 400 mg daily or placebo. The experience of the 1509 
bezafibrate treated patients, in tertiles of on-treatment increments in the ratio of HDL-C to 
total cholesterol (%HDL-C), was compared with that of the 1517 patients in the placebo 
group, to examine the effect of %HDL-C changes on ail-cause and cardiac mortality. 
Results Over a mean follow-up period of 8.2 years the mortality rate was 15.2% in tne 
placebo group and 13.9% in the bezafibrate group (~~0.33). Bounds for each on-treat- 
ment tertile of %HDL-C change were 1 (-4.8% to +2.2%); 2 (+2.2% to +5.1%); and 3 
(+5.1% to +19.7%). All-cause mortality rates were 17.3% (n=497), 13.4% (n=514), and 
11 .O% (n=498) in tertiles 1, 2 and 3, respectively (p=O.O2). The reduction rn all-cause 
mortality reflected a highly significant decline in the cardiac mortality rate with increasing 
increments in %HDL-C (placebo group - 8.9 %; tertile 1 - 10.9%; tertile 2 5.8%; tertile 3 
5.6%; p=O.O02). Multivariate adjustment for baseline clinical characteristics and lipid 
values confirmed increased %HDL-C levels as an independent predictor of improved sur- 
vival, compared to the placebo group (all-cause mortality: HR= 0.85 [95% Cl 0.65-l ,121 
and 0.69 95% [Cl 0.51-0.931 for tertiles 2 and 3 respectively; cardiac modality: HR= 0.61 
(95% Cl 0.41-0.911 and 0.58 [95% Cl 0.38-0.881 for tetiles 2 and 3 respectively). Tertile 1 
patients exhibited increased all-cause and cardiac mortality hazard (HR= 1.22 [95% Cl 
0.95-I ,581 and 1.30 [95% Cl 0.94-l ,801 respectively), compared to the placebo group. 
Conclusions In CHD patients with HDL-C ~45 mg/dL, successful modification of the 
fraction of total serum cholesterol contained in the HDL moiety with bezafibrate therapy, 
is independently associated with improved long-term survrval. 
9:15 a.m. 
876-4 Fenofibrate Lowers Small Low-Density Lipoprotein With 
No Change in Total Low-Density Lipoprotein 
Cholesterol 
H. Robert Superko, Sherna Madan, David Tonnemacher, Nicolas Chronos, Brenda 
Garrett, Dennis Sheehan, Elaine Raul, Steve Frohwein, Kenneth McGrath, Jr.. American 
Cardiovascular Research Institute, Atlanta, GA, Berkeley HeartLab. Berkeley, CA 
Purpose: Differences in the distribution of 7 LDL subclasses is finked to CAD risk and 
arteriographic outcome. We hypothesized that fenofibrate would have a beneficial effect 
on LDL subclass distribution in normocholesterolemic patients. 
Methods: 50 patients were treated with fenofibrate for dyslipidemia. Fasbng blood was 
analyzed prior to. and a mean of 3.8 months following, fenofibrate treatment (200 mgld). 
Fasting blood was analyzed for triglycerides (TG, mg/dl), total cholesterol (TC). LDLC 
and HDLC by enzymatic methods, 7 LDL and 5 HDL subclasses (%) by S3-Gradient Gel 
Electrophoresis using duplicate measures and internal standards and controls calrbrated 
to analytic ultracentrifugation at the University of California. Data was analyzed using the 
patient as their own control. 
Results: Mean&D baseline values (mg/dl) were: TC 185+_46, LDLC 100132, HDLC 
44.8+12.9. TG ?03+161. Fenofibrate treatment resulted in a sianifrcant reduction in tria- 
lycer~des (-26.6%, p<O.Ol), a significant increase in HDLC (+10.7%, p-zO.001) and no sig- 
nificant change in total or LDLC. The atherogenic small LDL region Illa+b was 
significantly reduced (pcO.02). 
LDL I LDLIla LDL Ilb LDL llla LDL LDL LDL IVb 
lllb IVa 
Baselrne 19.827. 15.3+5. 20.925. 23.8+7. 9.0+5.4 6.3i3.2 5.09.7 
8 3 9 0 
PostFenofibrate 25.228. 20.0+5. 23.025. 17.827. 5.79.8 4.9i2.9 3.5i2.2 
2 4 2 1 
P 0.07 0.004 0.02 0.01 0.02 0.17 0.004 
% Change +27.3 +30.7 +lO.O -25.2 -36.7 -22.2 -30.0 
9:30 a.m. 
876-5 Rosiglitazone Increases High-Density Lipoprotein 
Cholesterol Levels in Patients With Type 2 Diabetes 
Conclusion: RSG improved HDLC and total cholesterol:HDLC ratio over 24 months in 
Type 2 diabetes patients, More marked improvement was shown in patrents at greater 
CVD risk (ie, low HDLC [c40 mg/dL] and high total cholesterol:HDLC [x6]). 
HDLC concentration following treatment with RSG, mgidL 
All patients Baseline HDLC ~40 mgfdL Baseline HDLC 240 mg/dL 
n=269 n=99 n=170 
Baseline 45.3 33.1 52.5 
6 months 50.4 39.2 56.8 
12 months 51.2 39.7 58.1 
18 months 52.1 41.7 58.1 
24 months 51.9 41.3 58.1 
9:45 a.m. 
876-6 C-Reactive Protein Is Reduced During Ezetimibe 
Coadministration With Simvastatin in Patients With 
Primary Hypercholesterolemia 
Philip Saqer, Lorenzo Melani, Leslie Lipka, John Strony, Ramachandran Suresh, Enrico 
Veltri. the Ezetimibe Study Group, Schering-Plough Research Institute, Kenilworth. NJ 
Background: C-reactive protein (CRP), a marker of inflammation, is a novel risk factor 
for CHD; ezetimibe (EZE) co-admimstered with a statin significantly improves the lipid 
profile but its effect on CRP is unknown. 
Methods: EZE coadministered with simvastatin (SIMV) was evaluated in a randomized, 
double-blind, placebo (PBO)-controlled study in 668 patients with primary hypercholes- 
terolemia. After NCEP diet, a drug washout and 4.wk, single-blind, PBO lead-in period, 
oatients with baseline LDL-C 2145 to Q50 ma/d1 and TG ST50 ma/d1 were randomized to 
; of the following administered daily for 12 consecutive wks: EZE;O mg; SIMV 10, 20,40 
or 80 mo: EZE 1Oma + SIMV 10.20.40 or 80ma: or PBO. 
Results: Pooled EZE + SIMV reduced LDL-C from baseline by 49.9% versus pooled 
SIMV alone (36.1%, PcO.01) and co-administration was superior to statin alone at each 
SIMV dose. Overall, median % reductrons in CRP from baseline were almost 2X greater 
with pooled EZE + SIMV versus pooled SIMV alone (-34.8% versus -18.2%, P<O.Ol). 
Median CRP was reduced in pooled EZE + SIMV to 0.180 mg/dL and with SIMV to 0.215 
mg/dL (P=O.O3). CRP reductions by EZE + SlMVlO were comparable to SIMVBO. 
